Clear cell endometrial carcinoma represents an uncommon and poorly understood entity. Data from molecular/genomic profiling highlighted the importance of various signatures in assessing the prognosis of endometrial cancer according to four classes of risk (POLE mutated, MMRd, NSMP, and p53 abnormal). Unfortunately, data specific to clear cell histological subtype endometrial cancer are lacking. More recently, data has emerged to suggest that most of the patients (more than 80%) with clear cell endometrial carcinoma are characterized by p53 abnormality or NSMP type. This classification has important therapeutic implications. Although it is an uncommon entity, clear cell endometrial cancer patients with POLE mutation seem characterized by a good prognosis. Chemotherapy is effective in patients with NSMP (especially in stage III and IV) and patients with p53 abnormal disease (all stages). While, preliminary data suggested that patients with MMRd are less likely to benefit from chemotherapy. The latter group appears to benefit much more from immune checkpoint inhibitors: recent data from clinical trials on pembrolizumab plus lenvatinib and nivolumab plus cabozantinib supported that immunotherapy plus tyrosine kinase inhibitors (TKI) would be the most appropriate treatment for recurrent non-endometrioid endometrial cancer (including clear cell carcinoma) after the failure of platinum-based chemotherapy. Moreover, ongoing clinical trials testing the anti-tumor activity of innovative products will clarify the better strategies for advanced/recurrent clear cell endometrial carcinoma. Further prospective evidence is urgently needed to better characterize clear cell endometrial carcinoma. (C) 2022 Elsevier Inc. All rights reserved.

Bogani, G., Ray-Coquard, I., Concin, N., Ngoi, N. Y. L., Morice, P., Enomoto, T., Takehara, K., Denys, H., Lorusso, D., Coleman, R., Vaughan, M. M., Takano, M., Provencher, D., Sagae, S., Wimberger, P., Póka, R., Segev, Y., Kim, S. I., Kim, J., Candido Dos Reis, F. J., Mariani, A., Leitao, M. M., Makker, V., Rustum, N. A., Vergote, I., Zannoni, G. F., Tan, D. S. P., Mccormack, M., Bini, M., Lopez, S., Raspagliesi, F., Panici, P. B., Di Donato, V., Muzii, L., Colombo, N., Scambia, G., Pignata, S., Monk, B. J., Clear cell carcinoma of the endometrium, <<GYNECOLOGIC ONCOLOGY>>, 2022; 164 (3): 658-666. [doi:10.1016/j.ygyno.2022.01.012] [https://hdl.handle.net/10807/232461]

Clear cell carcinoma of the endometrium

Lorusso, Domenica;Mariani, Andrea;Zannoni, Gian Franco;Scambia, Giovanni;
2022

Abstract

Clear cell endometrial carcinoma represents an uncommon and poorly understood entity. Data from molecular/genomic profiling highlighted the importance of various signatures in assessing the prognosis of endometrial cancer according to four classes of risk (POLE mutated, MMRd, NSMP, and p53 abnormal). Unfortunately, data specific to clear cell histological subtype endometrial cancer are lacking. More recently, data has emerged to suggest that most of the patients (more than 80%) with clear cell endometrial carcinoma are characterized by p53 abnormality or NSMP type. This classification has important therapeutic implications. Although it is an uncommon entity, clear cell endometrial cancer patients with POLE mutation seem characterized by a good prognosis. Chemotherapy is effective in patients with NSMP (especially in stage III and IV) and patients with p53 abnormal disease (all stages). While, preliminary data suggested that patients with MMRd are less likely to benefit from chemotherapy. The latter group appears to benefit much more from immune checkpoint inhibitors: recent data from clinical trials on pembrolizumab plus lenvatinib and nivolumab plus cabozantinib supported that immunotherapy plus tyrosine kinase inhibitors (TKI) would be the most appropriate treatment for recurrent non-endometrioid endometrial cancer (including clear cell carcinoma) after the failure of platinum-based chemotherapy. Moreover, ongoing clinical trials testing the anti-tumor activity of innovative products will clarify the better strategies for advanced/recurrent clear cell endometrial carcinoma. Further prospective evidence is urgently needed to better characterize clear cell endometrial carcinoma. (C) 2022 Elsevier Inc. All rights reserved.
2022
Inglese
Bogani, G., Ray-Coquard, I., Concin, N., Ngoi, N. Y. L., Morice, P., Enomoto, T., Takehara, K., Denys, H., Lorusso, D., Coleman, R., Vaughan, M. M., Takano, M., Provencher, D., Sagae, S., Wimberger, P., Póka, R., Segev, Y., Kim, S. I., Kim, J., Candido Dos Reis, F. J., Mariani, A., Leitao, M. M., Makker, V., Rustum, N. A., Vergote, I., Zannoni, G. F., Tan, D. S. P., Mccormack, M., Bini, M., Lopez, S., Raspagliesi, F., Panici, P. B., Di Donato, V., Muzii, L., Colombo, N., Scambia, G., Pignata, S., Monk, B. J., Clear cell carcinoma of the endometrium, <<GYNECOLOGIC ONCOLOGY>>, 2022; 164 (3): 658-666. [doi:10.1016/j.ygyno.2022.01.012] [https://hdl.handle.net/10807/232461]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/232461
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 20
social impact